Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
ALS
Neuromuscular Ultrasound in ALS
Amyotrophic Lateral Sclerosis (ALS) is a progressive fatal neurodegenerative disease affecting motor neurons. Early diagnosis is essential for the success of clinical trials and objective biomarkers are needed for monitoring…
- Trial name
- NCT01785550
- Testing
- Ultrasound of nerve and muscle
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Duke University
Amyotrophic Lateral Sclerosis
Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology.
- Trial name
- LARMOMIQUE (NCT04953286)
- Testing
- Measure of visual acuity, Interferometry, Samples of basal tears
- Where
- 3 sites in France
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Neuromuscular Diseases (NMD), ALS (Amyotrophic Lateral Sclerosis)
Invasive Home Ventilation in Denmark
The aim of this study is to describe national trends over the past 10 years in patients receiving invasive home mechanical ventilation (HMV) in Denmark.
- Conditions
- Neuromuscular Diseases (NMD), ALS (Amyotrophic Lateral Sclerosis), Spinal Cord Injuries (SCI), Duchenne Muscular Dystrophy (DMD)
- Trial name
- HOMEVENT DK (NCT07467187)
- Where
- Denmark
- Volunteers
- 450 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Amyotrophic Lateral Sclerosis
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis
The preclinical rationale for tauroursodeoxycholic acid (TUDCA) use in treating patients with amyotrophic lateral sclerosis (ALS) stems from the demonstration of antioxidant, antiapoptotic and neuroprotective properties of TUDCA…
- Trial name
- TUDCA-ALS (NCT00877604)
- Testing
- tauroursodeoxycholic acid (TUDCA)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Amyotrophic Lateral Sclerosis (ALS)
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT07169175
- Testing
- SNUG01
- Where
- 4 sites in United States, China
- Volunteers
- 21 people
- Sponsor
- SineuGene Therapeutics Co., Ltd.
Amyotrophic Lateral Sclerosis
CuATSM Compared With Placebo for Treatment of ALS/MND
Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and efficacy of CuATSM in patients with ALS/MND.
- Trial name
- NCT04082832
- Testing
- Cu(II)ATSM
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Amyotrophic Lateral Sclerosis
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder and therapeutic options are limited. The rho kinase (ROCK) inhibitor Fasudil was shown to be neuroprotective, induced axonal regeneration and…
- Trial name
- ROCK-ALS (NCT03792490)
- Testing
- Fasudil
- Where
- 15 sites in France, Germany and 1 more
- Volunteers
- 120 people
- Sponsor
- University Medical Center Goettingen
Gene Mutation
Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation
The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of RAG-17 in adult amyotrophic lateral sclerosis (ALS) patients with SOD1 mutation.
- Trial name
- CREATION (NCT05903690)
- Testing
- RAG-17
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Tiantan Hospital
Amyotrophic Lateral Sclerosis
Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS)
Patients with neuropathic diseases are experiencing increasing muscle weakness, loss of muscle strength and functional abilities during their illness.
- Trial name
- ALS-project (NCT01504009)
- Testing
- Muscle training
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- University of Southern Denmark
Amyotrophic Lateral Sclerosis, ALS
Multicenter ALS Imaging Study
This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year.
- Trial name
- NCT06735014
- Testing
- Magnetic Resonance Imaging, Plasma neurofilament light chain (NfL) quantification
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Minnesota
Amyotrophic Lateral Sclerosis (ALS), Non Invasive Ventilation (NIV)
Dynamic Impact of NIV on Diaphragmatic Ultrasound in Patients With Amyotrophic Lateral Sclerosis
The goal of this pilot observational study is to learn about the dynamic impact of the non invasive ventilation on the diaphragm in patient with amyotrophic lateral sclerosis.
- Trial name
- EchoDia (NCT07170865)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Grenoble
Primary Lateral Sclerosis
Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
Objective: The objectives of this protocol are: to develop and maintain a repository of clinically characterized patients with primary lateral sclerosis for future research protocols, to characterize the natural history of…
- Trial name
- NCT00015444
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis, Noninvasive Ventilation
Patient's TeleMonitoring With Amyotrophic Lateral Sclerosis Treated by Non Invasive Ventilation at Home.
Single-center, prospective pilot study on patients with amyotrophic lateral sclerosis fitted with noninvasive ventilation. The objective is to assess the satisfaction of remote monitoring of patients on non-invasive ventilation…
- Trial name
- TS-VAD (NCT04797845)
- Testing
- teleconsultation
- Where
- France
- Volunteers
- 33 people
- Sponsor
- University Hospital, Toulouse
ALS (Amyotrophic Lateral Sclerosis)
A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients
The goal of this VA demonstration project is to show that the Brain-computer interface (BCI) technology is a clinically practical and important new communication and control option that can improve the lives of veterans with…
- Trial name
- ALS (NCT00786032)
- Testing
- BCI Device
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- US Department of Veterans Affairs
Amyotrophic Lateral Sclerosis
Impact of Nuedexta on Bulbar Physiology and Function in ALS
Nuedexta is FDA approved for the treatment of pseudobulbar affect in ALS patients and anecdotal reports of improvements in speech, salivation or swallowing have been reported.
- Trial name
- NCT03883581
- Testing
- dextromethorphan HBr and quinidine sulfate
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Florida
Amyotrophic Lateral Sclerosis
Longitudinal Evaluation of Short-Chain Fatty Acid Profiles During the Natural Disease Course and a Mediterranean Diet Intervention in Amyotrophic Lateral Sclerosis Patients
This observational study explored the connection between the gut microbiota and the brain in patients with amyotrophic lateral sclerosis (ALS), specifically the modulation of short-chain fatty acids during disease progression and…
- Trial name
- IMPACT-ALS (NCT07178067)
- Testing
- Mediterranean diet
- Where
- Romania
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures
Amyotrophic Lateral Sclerosis
Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS
ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and…
- Trial name
- NCT01771640
- Testing
- intrathecal injection
- Where
- Iran
- Volunteers
- 8 people
- Sponsor
- Royan Institute
Amyotrophic Lateral Sclerosis (ALS), Dysphagia
Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow in Patients Living With ALS
Prospective, single-arm pilot study evaluating transcutaneous electrical nerve stimulation of the superior laryngeal nerve (TENS-SLN) in individuals with ALS.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Dysphagia, Dystussia
- Trial name
- NCT07606235
- Testing
- Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow
- Volunteers
- 5 people
- Sponsor
- Nova Southeastern University
Amyotrophic Lateral Sclerosis
Reinnervation and Neuromuscular Transmission in ALS
The aim of this study is to describe the changes in the neuromuscular connection in patients with amyotrophic lateral sclerosis (ALS). The study consist of three substudies that have the following main hypothesis: 1.
- Trial name
- RANTAL (NCT06219759)
- Testing
- Observational study
- Where
- Denmark
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Aarhus